Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

导出原文传递

翻译打印收藏纠错

作者： Grunwald, Viktor ^[1] ; Voss, Martin H. ^[2] ; Rini, Brian, I ^[3] ; Powles, Thomas ^[4] ; Albiges, Laurence ^[5] ; Giles, Rachel H. ^[6] ; Jonasch, Eric ^[7]

作者单位： Queen Mary Univ London, Barts Canc Inst, London, England ^[1] Univ Hosp Essen, Interdisciplinary GU Oncol, West German Canc Ctr Essen, Clin Urol, Essen, Germany ^[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA ^[3] Univ Paris Saclay, Gustave Roussy Inst, Villejuif, France ^[4] Int Kidney Canc Coalit, Duivendrecht, France ^[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA ^[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA ^[7]

发布时间 2021-04-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The British journal of cancer

2020年123卷6期

898-904页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

The British journal of cancer

相似文献

The British journal of cancer

相关期刊

检索历史清除